Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis.
Study Design
- 研究タイプ
- systematic review
- サンプルサイズ
- 1658
- 介入
- Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis. various dietary supplements (Nutrafol, apple extract, tocotrienols, pumpkin seed oil, Cistanche/Lami
- 比較対照
- Placebo
- 効果の方向
- Positive
- バイアスリスク
- Moderate
Abstract
BACKGROUND: In recent years, androgenetic alopecia (AGA) has emerged as a significant public health concern due to its high prevalence and progressive nature. In addition to progressive scalp thinning and hair loss, patients often experience psychological distress and diminished quality of life. While standard treatments such as finasteride and minoxidil are effective, their side effects and adherence issues limit long-term use, making the exploration of safe and accessible intervention strategies essential. Dietary supplements, claimed to promote hair growth by inhibiting androgen pathways and improving the follicular microenvironment, have become an attractive adjunct for both clinicians and patients due to their low cost and ease of use. However, existing studies have limitations, including the diversity of supplements, small sample sizes, and the lack of direct comparisons among different supplements, making it unclear how they compare in terms of efficacy and safety. This study aims to use a network meta-analysis (NMA) to compare the effectiveness and safety of various dietary supplements based on outcomes such as hair density and terminal hair density, providing evidence-based support for clinical decision-making. METHODS: A systematic search was conducted in English-language databases such as PubMed, Cochrane Library, Embase, and Web of Science for randomized controlled trials (RCTs) investigating the use of dietary supplements for treating AGA. Stata 16.0 software was used for network meta-analysis, and Revman 5.4 software was utilized for evaluating study quality and bias risk; additionally, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework was applied to rate the certainty (quality) of evidence for the included studies. RESULTS: A total of 19 RCTs involving 1,658 AGA patients were included, with 894 patients in the supplement group and 764 in the control group. Sixteen dietary supplements were investigated. Results showed that compared with placebo, standardized plant extracts (Nutrafol), apple extract (AMSbzs, AMS), tocotrienols, pumpkin seed oil (PSO), and a compound extract of Cistanche and Laminaria (MK-R7) significantly improved hair density. Multi-component supplements (ALRV5XR), standardized plant extracts (Nutrafol), and probiotics effectively increased terminal hair density. In blind doctor assessments, PSO, capsaicin-isoflavones (CI), saw palmetto extract (ESR), Omega 3&6, Lambdapil, Nutrafol, and Multi-component supplements (AGA-P) showed higher hair regeneration scores than placebo or conventional treatments. No significant differences were found between interventions in terms of the terminal-to-vellus hair ratio. Overall, all dietary supplements were found to be well-tolerated. CONCLUSION: Dietary supplements have a positive impact on hair density, terminal hair density, and blind doctor evaluations in patients with androgenetic alopecia, with good tolerability. They may serve as beneficial adjuncts or alternatives to conventional treatments. Future large-scale, high-quality RCTs are needed to verify these findings. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251130173, Identifier CRD420251130173.
Full Text
Figures
Figure 1
PRISMA flow diagram for the systematic review and network meta-analysis evaluating the effects of dietary supplements on androgenetic alopecia.
flowchart
Figure 2
Network geometry diagram showing the available direct comparisons among dietary supplements studied for androgenetic alopecia treatment.
diagram
Figure 3
Forest plot or league table from the network meta-analysis ranking dietary supplements by their efficacy on hair density or growth outcomes in androgenetic alopecia.
forest_plot
Figure 4
SUCRA probability rankings of dietary supplements for improving hair-related outcomes in androgenetic alopecia patients.
chart
Figure 5
Risk of bias assessment or quality evaluation of the trials included in the network meta-analysis of dietary supplements for androgenetic alopecia.
chartTables
Table 1
| Supplement | Main components and typical dosages |
|---|---|
| ESR | ① Betasitosterol (50 mg), saw palmetto extract (200 mg;), lecithin (50 mg), inositol (100 mg), phosphatidyl choline (25 mg), niacin (15 mg), biotin (100 μg); ② Dry plant extract (320 mg) |
| PSO | Capsules (400 mg); pumpkin seed oil (oleic acid, linoleic acid, linolenic acid) |
| FSE-M | Fenugreek seed extract (300 mg), niacinamide (18 mg), pantothenic acid (6 mg), multivitamins (145 mg), zinc (5 mg) |
| Tocotrienol | Mixed capsules (50 mg; 30.8% alphatocotrienol; 56.4% gammatocotrienol; 12.8% deltatocotrienol; 23 IUs alphatocopherol) |
| Omega 3&6 | Fish oil (460 mg), blackcurrant seed oil (460 mg), vitamin E (5 mg), vitamin C (30 mg), lycopene (1 mg) |
| MK-R7 | Extract of cistanche tubulosa (150 mg), extract of |
| AGA-P | |
| Probiotics | Capsules (5 × 109 CFU); |
| CI | Capsaicin (6 mg); isoflavone (75 mg) |
| Viviscal | Vitamin C, zinc, AminoMar (shark powder and mollusk powder; 452.9 mg), horsetail extract (24.5 mg), flax seed extract (50 mg) |
| Nutrafol | Capsules of synergen complex, saw palmetto, maca, astaxanthin, curcumin, tocotrienols |
| AMSbzs | AMS with maltodextrins (400 mg), biotin (0.20 mg), selenomethionine (80.0 μg), zinc (21.0 mg) |
| AMS | Apple extract (from chlorogenic acid, procyanidin B2) |
| PPT5α | Saw palmetto (160 mg); pumpkin seed oil (100 mg); pomegranate extract (50 mg); zinc (10 mg); amino acids (50 mg L-cystine, 50 mg L-methionine), hydrolyzed collagen (250 mg); hyaluronic acid (25 mg), etc. |
| ALRV5XR | Capsules (842 mg); plant extracts ( |
| Lambdapil | L-cystine (1,000 mg), S repens (100 mg), |
Table 2
| Treatment | Hair density | Rank | Final hair density | Rank | Blind assessment by doctors | Rank | Final hair/soft fur | Rank |
|---|---|---|---|---|---|---|---|---|
| Lambdapil | — | — | — | — | 46.0% | 5 | — | — |
| ALRV5XR | — | — | 99.0% | 1 | — | — | 86.70% | 1 |
| Probiotics | 20.90% | 9 | 51.80% | 3 | — | — | 78.60% | 2 |
| FSE-M | 30.10% | 8 | 41.50% | 5 | — | — | — | — |
| AGA-P | — | — | — | — | 25.60% | 8 | — | — |
| Tocotrienol | 74.10% | 3 | — | — | — | — | — | — |
| PSO | 52.60% | 5 | — | — | 73.10% | 2 | — | — |
| CI | — | — | — | — | 71.60% | 3 | — | — |
| Nutrafol | 81.10% | 1 | 80.80% | 2 | 38.90% | 7 | 3.10% | 5 |
| ESR | — | — | — | — | 64.80% | 4 | — | — |
| PPT5α | — | — | 18.30% | 6 | — | — | — | — |
| AMS | 72.60% | 4 | — | — | — | — | — | — |
| Viviscal | 35.70% | 7 | 45.80% | 4 | — | — | — | — |
| MK-R7 | 52.30% | 6 | — | — | — | — | — | — |
| AMSbzs | 76.60% | 2 | — | — | — | — | — | — |
| Omega 3&6 | — | — | — | — | 40.30% | 6 | 42.60% | 3 |
| Finasteride | — | — | — | — | 83.30% | 1 | — | — |
| Placebo | 3.90% | 10 | 12.70% | 7 | 6.40% | 9 | 39% | 4 |
Table 3
| Treatment | Diarrhea ( | Flatulence ( | Itchy scalp ( | Generalized pruritus ( | Constipation ( | Loss of appetite ( | Gastrointestinal discomfort ( | Stomachache ( |
|---|---|---|---|---|---|---|---|---|
| Lambdapil | — | 1 | — | — | — | — | — | — |
| ALRV5XR | — | — | 1 | — | — | — | — | — |
| Probiotics | — | 2 | — | — | — | — | — | — |
| FSE-M | — | 2 | — | — | 1 | — | — | — |
| PSO | — | — | — | 1 | — | — | 1 | — |
| Nutrafol | — | 1 | — | — | — | — | 3 | — |
| ESR | — | — | — | — | — | 1 | — | — |
| PPT5α | 1 | — | — | — | — | — | — | — |
| AMSbzs | — | — | — | — | — | — | 1 | 2 |
| AMS | — | — | — | — | — | — | 3 | 2 |
| MK-R7 | — | 1 | — | — | — | — | — | — |
Table 4
| Intervention | Cases ( | Duration (days) | Treatment discontinuation (yes/no) |
|---|---|---|---|
| Lambdapil | 1 (2.8%) | NI | Yes |
| Probiotics | 2 (1.4%) | 7–14 | No |
| FSE-M | 3 (5.3%) | 3 | No |
| PSO | 2 (2.6%) | NI | No |
| Nutrafol | 4 (1.8%) | NI | No |
| ESR | 1 (0.8%) | NI | No |
| PPT5α | 1 (2.1%) | NI | Yes |
| AMSbzs | 3 (1.2%) | NI | No |
| AMS | 5 (6.2%) | NI | No |
| MK-R7 | 1 (1.0%) | NI | No |
Table 5
| Certainty assessment | Effect | Quality | ||||||
|---|---|---|---|---|---|---|---|---|
| No. of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Effect size (95% CI) | |
| Hair density | ||||||||
| 10 | RCTS | No serious | No serious | No serious | No serious | Serious | SMD = 0.52, 95% CI: 0.29, 1.32 | Moderate |
| Final hair density | ||||||||
| 7 | RCTS | Serious | No serious | No serious | No serious | Serious | SMD = 0.58, 95% CI: 0.24, 0.91 | Low |
| Blind assessment by doctors | ||||||||
| 9 | RCTS | No serious | Serious | No serious | No serious | Serious | RR = 2, 95% CI: 1.23, 3.27 | Low |
| Final hair/soft fur | ||||||||
| 5 | RCTS | No serious | No serious | No serious | Serious | No serious | SMD = 0.14, 95% CI: −0.05, 0.34 | Moderate |
References
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
- Untitled
Used In Evidence Reviews
Similar Papers
Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2017
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
Annual review of nutrition · 2004
Secular trends in dietary intake in the United States.
Journal of the American Academy of Dermatology · 1998
Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Endocrine · 2017
Androgenetic alopecia: a review.
Journal of the American Academy of Dermatology · 2002
A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
Journal of the American Academy of Dermatology · 2017